Status:
COMPLETED
Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation
Lead Sponsor:
Universitas Padjadjaran
Collaborating Sponsors:
Radboud University Medical Center
Conditions:
Tuberculous Meningitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Tuberculous (TB) meningitis is the most severe manifestation of TB infection, leaving up to 50% of patients dead or neurologically disabled. Current treatment is similar to treatment of lung TB, altho...
Detailed Description
Introduction: In a recent clinical trial the investigators have shown that a higher dose of rifampicin administered intravenously (600 mg iv) during the first 2 weeks of treatment is safe and associa...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Probable/possible tuberculosis meningitis using uniform case definition
- Agree to participate in the study
Exclusion
- Patient with antituberculosis treatment within last 2 weeks.
- Increase liver function \>5x upper limit of normal
- Pregnancy
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01802502
Start Date
June 1 2013
End Date
April 1 2014
Last Update
June 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hasan Sadikin Hospital
Bandung, West Java, Indonesia, 40122